Trials / Recruiting
RecruitingNCT04382846
Novel Regimens in COVID-19 Treatment
Nitazoxanide in Treatment of COVID-19
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- Sponsor
- Tanta University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Nitazoxanide has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.
Detailed description
Nitazoxanide has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019. Some studies demonstrated the efficacy of combined regimen of nitazoxanide and azithromycin or ivermectin and chloroquine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nitazoxanide | Nitazoxanide |
Timeline
- Start date
- 2020-05-08
- Primary completion
- 2030-12-01
- Completion
- 2030-12-01
- First posted
- 2020-05-11
- Last updated
- 2020-12-04
Locations
2 sites across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04382846. Inclusion in this directory is not an endorsement.